About TherapeuticsMD, Inc.TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. We are developing advanced hormone therapy pharmaceutical products based on novel technologies that enable delivery of bioidentical hormones through a variety of dosage forms and administration routes. We also manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD ® and BocaGreenMD ® brands. More information is available at the following websites: www.therapeuticsmd.com , www.vitamedmd.com , www.vitamedmdrx.com , and www.bocagreenmd.com. Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company’s expectations with respect to the design, the timing, and the size of enrollment in the SPRY Trial, as well as the ultimate results of the SPRY Trial; the Company’s belief that TX 12-002-HR may provide a safe and effective treatment for secondary amenorrhea at a lower dose versus currently approved oral therapies; the Company’s belief that if approved by the FDA, the Company’s oral progesterone candidate would have a significant competitive advantage; and the size of the hormone therapy market are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including but not limited to: timely and successful completion of clinical studies and the results thereof; challenges and costs inherent in product marketing; the risks and uncertainties associated with economic and market conditions; risks and uncertainties associated with the Company’s business and finances in general; and other risks detailed in the Company’s filings with the U.S. Securities and Exchange Commission including its annual report on Form 10-K filed on March 12, 2013, reports on Form 10-Q and Form 8-K, and other such filings. These forward-looking statements are based on current information that may change. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.